WO2005041957A1 - Derives d'oxindole et leur utilisation comme inhibiteurs de la phosphodiesterase de type 2 - Google Patents
Derives d'oxindole et leur utilisation comme inhibiteurs de la phosphodiesterase de type 2 Download PDFInfo
- Publication number
- WO2005041957A1 WO2005041957A1 PCT/IB2004/003404 IB2004003404W WO2005041957A1 WO 2005041957 A1 WO2005041957 A1 WO 2005041957A1 IB 2004003404 W IB2004003404 W IB 2004003404W WO 2005041957 A1 WO2005041957 A1 WO 2005041957A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- ester
- pharmaceutically acceptable
- prodrug
- pde2
- Prior art date
Links
- ZDSRIYLBMCGATH-UHFFFAOYSA-N CCN(C(C(C(Nc1cc(C)n[o]1)=O)c1c2)=O)c1cc1c2[o]cc1 Chemical compound CCN(C(C(C(Nc1cc(C)n[o]1)=O)c1c2)=O)c1cc1c2[o]cc1 ZDSRIYLBMCGATH-UHFFFAOYSA-N 0.000 description 1
- PKAZBMXDDJQETJ-UHFFFAOYSA-N CCN(C(C(C(Nc1nnc[s]1)=O)c1c2)=O)c1cc1c2[o]c(C)n1 Chemical compound CCN(C(C(C(Nc1nnc[s]1)=O)c1c2)=O)c1cc1c2[o]c(C)n1 PKAZBMXDDJQETJ-UHFFFAOYSA-N 0.000 description 1
- UZEYBPNMJZPEMJ-UHFFFAOYSA-N CCN(C(C(C(Nc1nnc[s]1)=O)c1c2)=O)c1cc1c2[s]cc1 Chemical compound CCN(C(C(C(Nc1nnc[s]1)=O)c1c2)=O)c1cc1c2[s]cc1 UZEYBPNMJZPEMJ-UHFFFAOYSA-N 0.000 description 1
- LTSKXVSYTXJDSB-UHFFFAOYSA-N CCN(C(C(C(OCC)=O)c1c2)=O)c1cc1c2[o]c(C)n1 Chemical compound CCN(C(C(C(OCC)=O)c1c2)=O)c1cc1c2[o]c(C)n1 LTSKXVSYTXJDSB-UHFFFAOYSA-N 0.000 description 1
- OQMLSKSSPKAKJQ-UHFFFAOYSA-N CN(C(C(C(Nc1nnc[s]1)=O)c1c2)=O)c1cc1c2[o]cc1 Chemical compound CN(C(C(C(Nc1nnc[s]1)=O)c1c2)=O)c1cc1c2[o]cc1 OQMLSKSSPKAKJQ-UHFFFAOYSA-N 0.000 description 1
- NAAWMJRLCVUWDG-UHFFFAOYSA-N CN(C(Cc1c2)=O)c1cc1c2[o]cc1 Chemical compound CN(C(Cc1c2)=O)c1cc1c2[o]cc1 NAAWMJRLCVUWDG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- a PDE2 inhibitor useful in the present invention is a compound that inhibits PDE2 and preferably has an IC 50 against human recombinant or purified PDE2 of less than about 5.0 ⁇ M.
- the IC 50 value of the PDE2 inhibitor is less than about 1.0 ⁇ M, more preferably about 0.2 ⁇ M or less.
- Preferred PDE2 inhibitors of the present invention do not significantly inhibit, i.e.
- PDE2 Binding Assay The activity of the test substances on human recombinant produced or isolated PDE2, and other PDE's is determined using the [ 3 H]cAMP scintillation proximity assay (SPA) kits from Amersham International (Little Chalfont, England). The SPA assays were performed using 96 well plates. The PDE SPA yttrium silicate beads (Amersham Biosciences®) bind preferentially to the linear nucleotide, GMP, compared to the cyclic nucleotide, cGMP.
- SPA [ 3 H]cAMP scintillation proximity assay
- IC 50 values of Compound 2 against purified PDE3 subtypes and PDE4 subtypes were all greater than 16.0 ⁇ M (data not shown).
- PDE2 Expression in Normal and Diseased Human Tissues Expression profiling of PDE2 was performed against a panel of RNAs from normal and diseased human tissues. The RNA panel is composed of samples from three donors per tissue and each RT-PCR reaction is performed with cDNA represents 40 ng of total RNA. A standard curve was run using varying quantities of PDE2 plasmid to quantify the amount of cDNA copies per sample. The average expression levels per tissue were calculated and binned into high (> 10 4 copies), medium (10 3 to 10 4 copies), and low (>10 3 copies) expression categories. The data for this experiment is provided in Table II below and would support alternate sites of action for PDE2 inhibitors. Table II. PDE2 Human Tissue Expression
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51540603P | 2003-10-29 | 2003-10-29 | |
US60/515,406 | 2003-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005041957A1 true WO2005041957A1 (fr) | 2005-05-12 |
Family
ID=34549407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2004/003404 WO2005041957A1 (fr) | 2003-10-29 | 2004-10-18 | Derives d'oxindole et leur utilisation comme inhibiteurs de la phosphodiesterase de type 2 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005041957A1 (fr) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012114222A1 (fr) * | 2011-02-23 | 2012-08-30 | Pfizer Inc. | Imidazo[5,1-f][1,2,4] triazines pour traiter les troubles neurologiques |
WO2014019979A1 (fr) | 2012-07-31 | 2014-02-06 | Boehringer Ingelheim International Gmbh | 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes |
WO2015096651A1 (fr) | 2013-12-23 | 2015-07-02 | Merck Sharp & Dohme Corp. | Composés pyrimidone carboxamide utilisés en tant qu'inhibiteurs de pde2 |
WO2015106032A1 (fr) | 2014-01-08 | 2015-07-16 | Intra-Cellular Therapies, Inc. | Produits et compositions pharmaceutiques |
WO2015164508A1 (fr) | 2014-04-23 | 2015-10-29 | Dart Neuroscience, Llc | Composés de [1,2,4]triazolo[1,5-a]pyrimidin-7-yle substitués utilisables en tant qu'inhibiteurs de pde2 |
WO2016149058A1 (fr) | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Composés de triazolyl pyrimidinone en tant qu'inhibiteurs de pde2 |
WO2016154081A1 (fr) | 2015-03-26 | 2016-09-29 | Merck Sharp & Dohme Corp. | Composés pyrazolyle pyrimidinone utilisés en tant qu'inhibiteurs de pde2 |
WO2016209749A1 (fr) | 2015-06-25 | 2016-12-29 | Merck Sharp & Dohme Corp. | Composés bicycliques pyrazolo/imidazolo substitués en tant qu'inhibiteurs de pde2 |
US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
EP3156405A1 (fr) | 2015-10-13 | 2017-04-19 | Boehringer Ingelheim International GmbH | Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide |
US10105349B2 (en) | 2014-12-06 | 2018-10-23 | Intra-Cellular Therapies, Inc. | Organic compounds |
US10160762B2 (en) | 2015-05-29 | 2018-12-25 | Merck Sharp & Dohme Corp. | 6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors |
US10174037B2 (en) | 2015-06-04 | 2019-01-08 | Merck Sharp & Dohme Corp. | Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors |
US10195201B2 (en) | 2015-05-05 | 2019-02-05 | Merck Sharp & Dohme Corp. | Heteroaryl-pyrimidinone compounds as PDE2 inhibitors |
US10239882B2 (en) | 2014-11-05 | 2019-03-26 | Dart Neuroscience (Cayman) Ltd. | Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors |
US10287293B2 (en) | 2015-07-01 | 2019-05-14 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as PDE2 inhibitors |
US10285989B2 (en) | 2015-05-15 | 2019-05-14 | Merck Sharp & Dohme Corp. | Pyrimidinone amide compounds as PDE2 inhibitors |
US10300064B2 (en) | 2014-12-06 | 2019-05-28 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2019101970A1 (fr) | 2017-11-23 | 2019-05-31 | Oslo University Hospital Hf | Traitement de la tachycardie |
US10357481B2 (en) | 2015-07-01 | 2019-07-23 | Merck Sharp & Dohme Corp. | Substituted triazolo bicyclic compounds as PDE2 inhibitors |
CN112996492A (zh) * | 2018-09-05 | 2021-06-18 | 阿姆斯特丹大学 | Pde11或pde2抑制剂用于治疗帕金森氏疾病的用途 |
CN114890897A (zh) * | 2022-05-31 | 2022-08-12 | 常州大学 | 一种pde2抑制剂内酯类衍生物及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4686224A (en) * | 1984-10-31 | 1987-08-11 | Pfizer Inc. | Oxindole antiinflammatory agents |
US4695571A (en) * | 1984-08-24 | 1987-09-22 | Pfizer Inc. | Tricyclic oxindole antiinflammatory agents |
US5057526A (en) * | 1988-03-24 | 1991-10-15 | Boehringer Mannheim Gmbh | Pharmaceutically active pyridinyl substituted 5,7-dihydropyrrolo-[3,2-f]benzoxazole-6-ones |
WO2002088139A1 (fr) * | 2001-04-30 | 2002-11-07 | Merck Patent Gmbh | Derives de 6h-oxazolo[4,5-e]indole utilises en tant que ligands du recepteur nicotinique de l'acetylcholine et/ou ligands serotoninergiques |
-
2004
- 2004-10-18 WO PCT/IB2004/003404 patent/WO2005041957A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4695571A (en) * | 1984-08-24 | 1987-09-22 | Pfizer Inc. | Tricyclic oxindole antiinflammatory agents |
US4686224A (en) * | 1984-10-31 | 1987-08-11 | Pfizer Inc. | Oxindole antiinflammatory agents |
US5057526A (en) * | 1988-03-24 | 1991-10-15 | Boehringer Mannheim Gmbh | Pharmaceutically active pyridinyl substituted 5,7-dihydropyrrolo-[3,2-f]benzoxazole-6-ones |
WO2002088139A1 (fr) * | 2001-04-30 | 2002-11-07 | Merck Patent Gmbh | Derives de 6h-oxazolo[4,5-e]indole utilises en tant que ligands du recepteur nicotinique de l'acetylcholine et/ou ligands serotoninergiques |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
CN103391941A (zh) * | 2011-02-23 | 2013-11-13 | 辉瑞大药厂 | 用于治疗神经障碍的咪唑并[5,1-f][1,2,4]三嗪类 |
US8598155B2 (en) | 2011-02-23 | 2013-12-03 | Pfizer Inc. | Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders |
WO2012114222A1 (fr) * | 2011-02-23 | 2012-08-30 | Pfizer Inc. | Imidazo[5,1-f][1,2,4] triazines pour traiter les troubles neurologiques |
US9200000B2 (en) | 2011-02-23 | 2015-12-01 | Pfizer Inc. | Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders |
EA022586B1 (ru) * | 2011-02-23 | 2016-01-29 | Пфайзер Инк. | ИМИДАЗО[5,1-f][1,2,4]ТРИАЗИНЫ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ |
WO2014019979A1 (fr) | 2012-07-31 | 2014-02-06 | Boehringer Ingelheim International Gmbh | 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes |
US9085584B2 (en) | 2012-07-31 | 2015-07-21 | Boehringer Ingelheim International Gmbh | Substituted pyrido[3,2-E][1,2,4]-triazolo[4,3-A]pyrazines for the treatment of central nervous system disorders |
WO2015096651A1 (fr) | 2013-12-23 | 2015-07-02 | Merck Sharp & Dohme Corp. | Composés pyrimidone carboxamide utilisés en tant qu'inhibiteurs de pde2 |
US9815796B2 (en) | 2013-12-23 | 2017-11-14 | Merck Sharp & Dohme Corp. | Pyrimidone carboxamide compounds as PDE2 inhibitors |
WO2015106032A1 (fr) | 2014-01-08 | 2015-07-16 | Intra-Cellular Therapies, Inc. | Produits et compositions pharmaceutiques |
US11186582B2 (en) | 2014-04-23 | 2021-11-30 | Dart Neuroscience, (Cayman) LTD. | Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as PDE2 inhibitors |
WO2015164508A1 (fr) | 2014-04-23 | 2015-10-29 | Dart Neuroscience, Llc | Composés de [1,2,4]triazolo[1,5-a]pyrimidin-7-yle substitués utilisables en tant qu'inhibiteurs de pde2 |
US10501465B2 (en) | 2014-04-23 | 2019-12-10 | Dart Neuroscience (Cayman) Ltd. | Substituted [1,2,4]triazolo[1,5-A]pyrimidin-7-yl compounds as PDE2 inhibitors |
US9932345B2 (en) | 2014-04-23 | 2018-04-03 | Dart Neuroscience (Cayman) Ltd. | Substituted [1,2,4]triazolo[1,5-A]pyrimidin-7-yl compounds as PDE2 inhibitors |
EP3597649A1 (fr) | 2014-04-23 | 2020-01-22 | Dart NeuroScience (Cayman) Ltd | Composés substitués de [1,2,4]triazolo[1,5-a]pyrimidine-7-yl utilisés en tant qu'inhibiteurs pde2 |
US10239882B2 (en) | 2014-11-05 | 2019-03-26 | Dart Neuroscience (Cayman) Ltd. | Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors |
US10300064B2 (en) | 2014-12-06 | 2019-05-28 | Intra-Cellular Therapies, Inc. | Organic compounds |
US10543194B2 (en) | 2014-12-06 | 2020-01-28 | Intra-Cellular Therapies, Inc. | Organic compounds |
US10105349B2 (en) | 2014-12-06 | 2018-10-23 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2016149058A1 (fr) | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Composés de triazolyl pyrimidinone en tant qu'inhibiteurs de pde2 |
US10358435B2 (en) | 2015-03-17 | 2019-07-23 | Merck Sharp & Dohme Corp. | Triazolyl pyrimidinone compounds as PDE2 inhibitors |
US10287269B2 (en) | 2015-03-26 | 2019-05-14 | Merck Sharp & Dohme Corp. | Pyrazolyl pyrimidinone compounds as PDE2 inhibitors |
WO2016154081A1 (fr) | 2015-03-26 | 2016-09-29 | Merck Sharp & Dohme Corp. | Composés pyrazolyle pyrimidinone utilisés en tant qu'inhibiteurs de pde2 |
US10195201B2 (en) | 2015-05-05 | 2019-02-05 | Merck Sharp & Dohme Corp. | Heteroaryl-pyrimidinone compounds as PDE2 inhibitors |
US10285989B2 (en) | 2015-05-15 | 2019-05-14 | Merck Sharp & Dohme Corp. | Pyrimidinone amide compounds as PDE2 inhibitors |
US10160762B2 (en) | 2015-05-29 | 2018-12-25 | Merck Sharp & Dohme Corp. | 6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors |
US10174037B2 (en) | 2015-06-04 | 2019-01-08 | Merck Sharp & Dohme Corp. | Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors |
WO2016209749A1 (fr) | 2015-06-25 | 2016-12-29 | Merck Sharp & Dohme Corp. | Composés bicycliques pyrazolo/imidazolo substitués en tant qu'inhibiteurs de pde2 |
US10647727B2 (en) | 2015-06-25 | 2020-05-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors |
US10357481B2 (en) | 2015-07-01 | 2019-07-23 | Merck Sharp & Dohme Corp. | Substituted triazolo bicyclic compounds as PDE2 inhibitors |
US10287293B2 (en) | 2015-07-01 | 2019-05-14 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as PDE2 inhibitors |
US10479794B2 (en) | 2015-10-13 | 2019-11-19 | Boehringer Ingelheim International Gmbh | Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide |
US10023575B2 (en) | 2015-10-13 | 2018-07-17 | Boehringer Ingelheim International Gmbh | Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide |
EP3156405A1 (fr) | 2015-10-13 | 2017-04-19 | Boehringer Ingelheim International GmbH | Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide |
US10875867B2 (en) | 2015-10-13 | 2020-12-29 | Boehringer Ingelheim International Gmbh | Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide |
US11691977B2 (en) | 2015-10-13 | 2023-07-04 | Boehringer Ingelheim International Gmbh | Cyclic ether derivatives of pyrazolo[1,5-A]pyrimidine-3-carboxyamide |
WO2019101970A1 (fr) | 2017-11-23 | 2019-05-31 | Oslo University Hospital Hf | Traitement de la tachycardie |
US11419874B2 (en) | 2017-11-23 | 2022-08-23 | Oslo University Hospital Hf | Treatment of tachycardia |
CN112996492A (zh) * | 2018-09-05 | 2021-06-18 | 阿姆斯特丹大学 | Pde11或pde2抑制剂用于治疗帕金森氏疾病的用途 |
CN114890897A (zh) * | 2022-05-31 | 2022-08-12 | 常州大学 | 一种pde2抑制剂内酯类衍生物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005041957A1 (fr) | Derives d'oxindole et leur utilisation comme inhibiteurs de la phosphodiesterase de type 2 | |
TWI352084B (en) | Gsk-3 inhibitors | |
JP5009155B2 (ja) | 新規な6−ホルミル−テトラヒドロプテリジン、その製造方法および特に癌に対する医薬品としてのその使用 | |
DE69836332T2 (de) | Benzyliden-1,3-dihydro-indol-2-on-derivate als inhibitoren von rezeptor tyrosin kinasen, insbesondere von raf kinasen | |
JP5102212B2 (ja) | プロテインキナーゼインヒビターとしてのピラゾロピリミジン | |
Er et al. | Novel substituted benzothiazole and Imidazo [2, 1-b][1, 3, 4] Thiadiazole derivatives: Synthesis, characterization, molecular docking study, and investigation of their in vitro antileishmanial and antibacterial activities | |
US20040097504A1 (en) | Compositions useful as inhibitors of jak and other protein kinases | |
JP2008516905A (ja) | Cdk1抗増殖活性を有する1,5−ナフチリジンアゾリジノン | |
EP3148539B1 (fr) | Inhibiteurs d'histone désacétylase, et compositions et méthodes d'utilisation de ceux-ci | |
TW200530251A (en) | Compositions useful as inhibitors of protein kinases | |
CN101646671A (zh) | 用作蛋白激酶抑制剂的化合物 | |
JP2008069178A (ja) | プロテインキナーゼのインヒビターとして有用なキノキサリン | |
EP1200415A1 (fr) | Composes diamino-1,2,4-triazole-acide carboxylique et derives de ces derniers utiles en tant qu'inhibiteurs de gsk-3 | |
JP2007513184A5 (fr) | ||
JP5995975B2 (ja) | Mtor阻害剤としてのモルホリノ置換尿素またはカルバメート誘導体 | |
JP4865785B2 (ja) | Cdk阻害剤としての置換1,5−ナフチリジンアゾリジノン | |
EP1668013B1 (fr) | Derives de pyrazolopyrrole utilises en tant qu'inhibiteurs de proteines kinases | |
JP2008516903A (ja) | 抗癌剤としての新規アザインドールチアゾリノン | |
JP2018138609A (ja) | ナフチリジンジオン誘導体 | |
JP5583845B2 (ja) | イミダゾピリダジニル化合物および癌に対するそれらの使用 | |
KR20150036046A (ko) | 히스톤 탈아세틸화 효소 억제제들과 그 조성물들 및 그 사용 방법들 | |
WO2020258971A1 (fr) | Dérivés d'hydrazone amide et leur utilisation dans la préparation de médicaments contre l'ostéoporose | |
US20080261974A1 (en) | Novel Chemical Compounds | |
JP3012338B2 (ja) | アリールおよびヘテロアリールアルコキシナフタレン誘導体 | |
US20040242869A1 (en) | Semicarbazides and their uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |